

The logo for 2curex, featuring the company name in a blue, sans-serif font. The '2' is stylized with a horizontal line extending from its base. The background of the slide is a photograph of a woman with long blonde hair laughing joyfully while holding a baby who is wearing a pink beanie and looking down.

2curex

The next wave in Precision Oncology

**ØU Life Science Investor Conference
26. May 2021**

Fernando Andreu, CEO & Ole Thastrup, CSO

Management changes February 1st

- Barcelona, 1964
- Chiron, Roche Diagnostics, Sysmex, Indivumed...
- IVD, Medical Devices, Oncology, Big Data – AI / ML
- CEO with strong focus in International Business Development

- Aarhus, 1976
- KPMG, CLC Bio, Qiagen, Gnosis Data Analysis...
- Software and Bioinformatics, Big Data – AI / ML
- CFO with CEO experience and strong focus in Business Development

- Ole Thastrup, former CEO and Founder, transitioned into the role of CSO with responsibility for clinical and scientific activities



Fernando Andreu
CEO



fa@2curex.com



Kenneth G. Johansen
CFO




kgj@2curex.com


-because cancer patients are individuals

Genomic Precision Oncology – helps only a small subset of patients

- 73% of US patients with advanced or metastatic cancer do not have a genetic biomarker to guide their therapy (single drug treatment). For combination therapy it is significantly lower.
- Genome-guided therapy achieves response in 11% of the treated patients.
- There is a **strong need for new tools to guide therapy decision making in oncology** and Functional Testing provides these tools.



IndiTreat® - a functional test monitoring drug efficacy and resistance



- Patient tumoroids are exposed to multiple mono- and combination therapies to predict efficacy and resistances.
- 2cureX has developed **proprietary know-how** over 15 years in all stages of the process (3D microtumors, drug gel arrays, analysis algorithms...) making our IndiTreat® assay the state of the art in Functional Testing.
- **A Functional Test is a new category in Companion Diagnostics** that can provide information where biomarker-based tests cannot.

- because cancer patients are individuals


The TICC trial (NCT03251612, www.clinicaltrials.gov)

Investigator Initiated Trial (IIT) trial (hospital in charge of endpoint, protocol, data analysis and publication)

The world's first prospective interventional trial

Patient group: end-stage (3 L) metastatic colorectal cancer patients

Primary Endpoint: Improve Progression-Free-Survival (PFS) from 20% (standard of care) to 40% after eight weeks of IndiTreat® guided treatment



The TICC trial (NCT03251612, www.clinicaltrials.gov)

Investigator Initiated Trial (IIT) trial (hospital in charge of endpoint, protocol, data analysis and publication)

The world's first prospective interventional trial

Patient group: end-stage (3 L) metastatic colorectal cancer patients

Primary Endpoint: Improve Progression-Free-Survival (PFS) from 20% (standard of care) to 40% after eight weeks of IndiTreat® guided treatment

The Primary endpoint of TICC was met:

Primary Endpoint: PFS after IndiTreat® guided treatment was 50%

-because cancer patients are individuals

The logo for 2cureX, featuring a stylized '2' followed by the word 'cureX' in a blue, sans-serif font.

Functional Testing is becoming "ready for prime time"

PubMed.gov search results for "cancer organoids". The search bar shows "cancer organoids" with a search button. Below the search bar are options for "Advanced", "Create alert", "Create RSS", and "User Guide". There are buttons for "Save", "Email", and "Send to". The results are sorted by "Best match" and "Display options" are available. A bar chart shows the number of results by year from 1946 to 2021, with a significant increase starting around 2015. Below the chart is a navigation bar for the National Cancer Institute Center for Biomedical Informatics & Information Technology, with links for "Data Sharing", "Data Commons", "Collaborations", "Resources", "News & Events", "Funding", "About", and "Search". The main content area is titled "Functional Precision Oncology for Cancer Treatment Selection" and includes a "Seminar Series" section for a talk on March 11, 2020, and a "Subscribe to Updates" button. There is also an "Upcoming Events" section for "Establishing Next Generation Dynamic Susceptibility Contrast MRI-Based Biomarkers for Neuro-oncologic Applications" on May 03, 2021.

- After years of being restricted to the research and academic environment, Functional Testing in Oncology is gaining momentum.
- While not yet mentioned in guidelines, the evidence and the awareness from clinicians are building up.

Screenshot of the AAGR 2021 Annual Meeting program page. The header includes "HOME / Session Search", "Virtual Meeting Platform", and "Sign in with Meeting Login". The main banner features the AAGR 2021 logo and the text "DISCOVERY SCIENCE DRIVING CLINICAL BREAKTHROUGHS". Below the banner is a "Program Planner Home" section with a "Share Page" and "Print Page" button. The session is titled "SESSION SY16.OD - Functional Precision Medicine in Cancer" and is scheduled for April 9, 2021, from 12:05 AM to 11:59 PM, available "On Demand". The description notes that presenters will participate in a Panel Discussion at 11:30 AM on April 15, 2021, and provides information about the session's focus on precision medicine and drug discovery.

- because cancer patients are individuals



2cureX is at the forefront based on solid foundation




-because cancer patients are individuals




Next Step: Market Access

- Mainstream sales require the products to be included in **reimbursement schemes** and in **clinical guidelines**. These are different country to country across Europe and require local knowledge. Expanding our distributor network is a top priority.
- While we are working on that, we are exploring alternative approaches to generate **sales revenue already in 2021**.
- In parallel, we are working to adapt our CE Marking to comply with the **new IVD Regulation (EU) 2017/746** that comes into force in May 2022 and will change the competitive landscape.



- because cancer patients are individuals

Roadmap I – Product Portfolio



- IndiTreat® can support therapy decision making in multiple stages throughout the patient journey.
- Our **first test** focuses on 3rd line of treatment in metastatic CRC.
- **Additional indications** within CRC are being developed.
- More than 1.9 M people worldwide (450,000 in Europe) were diagnosed with CRC last year, and approximately 950,000 (220,000 in Europe) died of it.
- We have ongoing studies for the application of IndiTreat® to other cancer entities such as **ovarian and pancreatic**.

-because cancer patients are individuals


Roadmap II – Geography



- In Q3 last year we announced the focus in 2021 would be on **Nordic countries**, extending to rest of Europe in 2022.
- Based on positive feedback after IndiTreat[®] mCRC 3L introduction, we decided to accelerate entry in selected European markets.
- Considering a combination of **market size and complexity of market access**, we prioritized for 2021, beyond Nordics, **Poland, Italy, France, Spain and Portugal**.
- Distribution agreements are in place in Nordics and Portugal, and under discussion in the rest of countries.

-because cancer patients are individuals

Roadmap III – Automation



- Currently, IndiTreat® is offered as a service.
- Samples are collected at the customer site and shipped to our facility in Copenhagen, where the 3D microtumors are grown and tested for drug sensitivity. A report is generated and sent back to the ordering physician.
- We have an ongoing project with prestigious **Hahn Schickard Institute** in Freiburg to automate substantial parts of our process.
- Having an **automated system** will allow us to open additional testing facilities and enable **geographic expansion beyond Europe**.

Financial Highlights



- Thanks to the Directed Issue in July 2020, we ended the year with a **solid cash position** (more than 5 times the operational CF usage of 2020).
- In May 2021 we successfully finalized a **warrant program** connected to the Directed Issue (rights for 2 455 000 warrants) providing 31 MSEK.
- Details about our 2020 activities and our plans can be found in the **Annual Report** that we will be releasing tomorrow (May 6th)
- 2cureX is listed in the Nasdaq First North Growth Market in Stockholm, under 2CUREX.

-because cancer patients are individuals

In summary

- Functional Testing will drive the next wave of Precision Oncology and addresses a much larger patient population than biomarker-based Companion Diagnostics
- 2cureX is leading this space with a solid and protected technology, a product in the market and strong clinical evidence to support it.
- The interventional clinical trial, TICC surpassed the primary endpoint.
- We have a clear Go-to-market plan. Distribution contracts signed or under discussion in major European countries. Working on reimbursement and clinical guidelines.
- We are getting ready for the regulatory change in 2022.
- Growth vectors: geography, portfolio and automation.
- An attractive risk profile in a business with high potential for growth.

- because cancer patients are individuals